Zimmer Partners LP Invests $2.99 Million in Roivant Sciences Ltd. (NASDAQ:ROIV)

Zimmer Partners LP purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 252,900 shares of the company's stock, valued at approximately $2,992,000.

Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Roivant Sciences during the fourth quarter worth about $39,000. PNC Financial Services Group Inc. increased its stake in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after acquiring an additional 1,507 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Roivant Sciences by 84.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after purchasing an additional 3,426 shares during the period. Finally, Blue Trust Inc. lifted its stake in shares of Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after purchasing an additional 6,667 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Insider Activity

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $10.95, for a total value of $1,095,000.00. Following the completion of the transaction, the chief operating officer now owns 1,077,197 shares in the company, valued at $11,795,307.15. This represents a 8.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now owns 39,799,611 shares in the company, valued at $456,501,538.17. This represents a 0.68% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,223,959 shares of company stock worth $13,450,035. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Trading Down 0.6%

NASDAQ:ROIV traded down $0.07 during mid-day trading on Monday, hitting $10.87. The company had a trading volume of 2,442,270 shares, compared to its average volume of 5,579,306. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The business has a fifty day simple moving average of $10.53 and a 200-day simple moving average of $11.05. The firm has a market capitalization of $7.76 billion, a price-to-earnings ratio of -72.46 and a beta of 1.23.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.